Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. by Evgeniy Evdoshenko, Alexandra Stepanova, Maria Shumilina, Maria Davydovskaya, Natalia Khachanova, Nikolay Neofidov, Ivan Kalinin, Ekaterina Popova, Ekaterina Dubchenko, Natalia Pozhidaeva, Andrey Volkov, Stella Sivertseva, Anna Prilenskaya, Nadezhda Malkova, Denis Korobko, Ilona Vergunova, Sergey Shchur, Gleb Makshakov

Get full text